| Chronic Obstructive Airway Disease
Perforomist vs Tudorza Pressair
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Perforomist vs Tudorza Pressair with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTudorza Pressair has a higher rate of injection site reactions vs Perforomist based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tudorza Pressair but not Perforomist, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Perforomist
Tudorza Pressair
At A Glance
Nebulization
Twice daily
Long-acting beta2-agonist (LABA)
Oral inhalation
Twice daily
Anticholinergic
Indications
- Chronic Obstructive Airway Disease
- Bronchitis, Chronic
- Pulmonary Emphysema
- Chronic Obstructive Airway Disease
Dosing
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema 20 mcg (one unit-dose vial) administered twice daily (morning and evening) by nebulization via standard jet nebulizer connected to an air compressor; total daily dose greater than 40 mcg is not recommended.
Chronic Obstructive Airway Disease One oral inhalation of 400 mcg twice daily (morning and evening approximately 12 hours apart).
Contraindications
- Use without an inhaled corticosteroid in patients with asthma
- Severe hypersensitivity to milk proteins
- Hypersensitivity to aclidinium bromide or any excipient
Adverse Reactions
Most common (>=2%) Diarrhea, nausea, nasopharyngitis, dry mouth, vomiting, dizziness, insomnia
Serious Angina, hypertension or hypotension, tachycardia, arrhythmias, hypokalemia, hyperglycemia, metabolic acidosis
Postmarketing Anaphylactic reactions, urticaria, angioedema, rash, bronchospasm
Most common (>=1%) Headache, nasopharyngitis, cough, diarrhea, sinusitis, rhinitis, toothache, fall, vomiting
Serious Paradoxical bronchospasm, worsening of narrow-angle glaucoma, worsening of urinary retention, immediate hypersensitivity reactions
Postmarketing Anaphylaxis, angioedema, urticaria, rash, bronchospasm, itching, nausea, dysphonia, blurred vision, urinary retention, tachycardia, stomatitis
Pharmacology
Long-acting beta2-adrenergic receptor agonist (LABA) that acts locally in the lung as a bronchodilator; stimulates adenyl cyclase to increase cyclic AMP levels, causing relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Aclidinium bromide is a long-acting antimuscarinic (anticholinergic) agent that inhibits M3 muscarinic receptors on airway smooth muscle, causing bronchodilation; the bronchodilatory effect is predominantly site-specific following inhalation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Perforomist
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (10/12)
Tudorza Pressair
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Perforomist
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (5/8)
Tudorza Pressair
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (0/8)
Humana
Perforomist
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Tudorza Pressair
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Perforomist.
No savings programs available for Tudorza Pressair.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PerforomistView full Perforomist profile
Tudorza PressairView full Tudorza Pressair profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.